View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 31, 2021

Bioventus exercises option to proceed with CartiHeal acquisition

Medical device company CartiHeal developed the Agili-C implant for treating cartilage and osteochondral defects.

US-based orthobiologics company Bioventus has decided to proceed with a previously agreed option structure to advance with its plans to acquire CartiHeal , developer of the Agili-C implant.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

As decided, Bioventus will make a $50m escrow payment to demonstrate its indication to acquire CartiHeal .

The decision comes after Bioventus reviewed a statistical analysis report of the pivotal clinical trial of the Agili-C implant, reimbursement coding analysis and market diligence related to commercialisation opportunities.

Notably, CartiHeal secured a $15m investment from Bioventus last year.

Both companies also agreed to an option structure under which Bioventus would acquire CartiHeal if the latter secured US Food and Drug Administration (FDA) approval for the Agili-C implant.

Bioventus can execute the potential transaction by exercising a call option provided under the option agreement. The agreement also provides CartiHeal with a put option, which can be exercised following premarket approval (PMA) of Agili-C implant by the FDA.

After such option rights are exercised, the completion of the transaction is subject to certain customary conditions.

Israel-headquartered CartiHeal developed the Agili-C implant for treating cartilage and osteochondral defects in the knee joints of patients without severe osteoarthritis.

Bioventus senior vice-president and chief science officer Alessandra Pavesio said: “The robust data generated from the pivotal clinical trial, a randomised controlled trial with Agili-C, demonstrated superiority over the surgical standard of care, microfracture and debridement, in knee injury and osteoarthritis outcome score (KOOS) overall compared to baseline.

“We believe this product could be a strong alternative for the approximately 650,000 US patients annually receiving microfracture or debridement along with other cartilage treatment options.

“In combination with our hyaluronic acid (HA) products, Agili-C represents an exciting potential new offering for our portfolio designed to address the spectrum of osteoarthritis disease.”

The Agili-C implant received FDA Breakthrough Device Designation in 2020. CartiHeal now plans to submit the clinical module of their PMA later this year.

 

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network